NCT04944069View on ClinicalTrials.gov

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

NAUnknownINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2025

Conditions
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Interventions
DRUG

Almonertinib

110 mg oral once daily

DRUG

Bevacizumab

15 mg/kg intravenous on Day 1 of 21 day cycles (every 3 weeks)

Trial Locations (1)

330006

The Second Afiliated Hospital of Nanchang University, Nanchang

Sponsors
All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

Second Affiliated Hospital of Nanchang University

OTHER